← Eichor
Study identifier: NCT07361237 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

Condition: NSCLC (Advanced Non-small Cell Lung Cancer)  ·  Sponsor: Tongji University

PhasePhase 1
Planned participants36
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Single dose: Fasting, oral administration, as a single dose, taken with warm water. Multiple doses: Fasting, oral administration, as a single dose, taken with warm water, once daily (dosing frequency may be adjusted based on study data), with 28 days as one cycle.

This description comes directly from the study's public registry record.

Talk to the study team

Shengli Liu  ·  86+13855102310  ·  slliu@jingmedicine.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai East HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07361237